TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: perception of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total number of bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Discouragement from wanting to smoke
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CK elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myoglobin elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: test anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Correct classification of subjects into quartiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of recommending surgical intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoglycaemia unawareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of ANGPTL4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCS difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood glucose six hours after presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in attention, information processing and executive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: nasopharyngeal discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in binge drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total alcohol intake in men
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ratio between wine and total alcohol in women
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall frequencies of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: severe dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: initial acceptance of the anesthetic induction mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in [Formula: see text]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in CS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in LT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesional size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in LOH events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in physicians' assessments of telangiectasia component of rosacea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in erythematotelangiectatic rosacea subtype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial scaling as an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Mean physical activity days per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean analgesic requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean VAS
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Nasal mucociliary clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean average pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference of pain on quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of dosage administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Incontinence Episode Frequency (IEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of 1-hour amount of urinary leakage (AUL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Odds of hypothermia (temperature < 36°C at the end of surgery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of reported wheeze
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Positive SPT prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dermatophagoides-specific IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportions of successful treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lymph nodes found
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Sensitivity of ICG-ePLND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung injury scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hematocrit (Hct) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total antipyrine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antipyrine half-life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intake of iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intake of niacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intake of calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: intake of zinc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in initial preference after receiving full information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intrinsic P-wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe affective distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 25-day sick leave
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Poor life control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduced incidence of myocardial infarctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased requirement for inotropic agents after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Earlier time to tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PAS
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of cleaning of the child's teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cavitated carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extraction of 'false teeth' (ebiino)
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day smoking cessation
Endpoint domain: Mortality/survival
Primary endpoint: Serum high-sensitivity C-reactive protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Homocysteine plasma level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: cumulative incidence of death or re-infarction
Endpoint domain: Mortality/survival
Primary endpoint: rates of recurrent ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neutrophil absolute decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nonreporting of PRO findings
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inadequate reporting standards for PRO findings
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Delay in publication of PRO results
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence rate of symptomatic stroke and systemic embolism (SE)
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence rate of major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: increased positive communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: thinking more about diabetes care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Progression Free Survival (PFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean measured glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Plasma progesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pregnanediol‐3‐glucuronide excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Saliva progesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Clinical grade of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fasting plasma secondary bile acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of major adverse cardiovascular events (MACE)
Endpoint domain: Mortality/survival
Primary endpoint: Correct responses on post training and follow-up tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: self‐ratings of vocal quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: physical effort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caffeine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: shear elastic modulus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dorsiflexion ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Volumetric PVP enhancement
Endpoint domain: Mortality/survival
Primary endpoint: Presence of squamous epithelium in specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital admission costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Readmission rate
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of primary endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in nightmares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sleep maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated glomerular hydraulic pressure (PGLO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cognitive functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain macrostructure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total TRS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of symptom-free patients at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median time to first symptomatic episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in IGA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of canine retraction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak anti‐Xa level >0.5 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients with peak anti‐Xa level in the target range (0.5 to 1.5 IU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of major and minor bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: toxic effects of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Adolescent prevention and cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GCS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum S100B level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporary palsy rates
Endpoint domain: Adverse events/effects
Primary endpoint: Stroke (nonfatal and fatal)
Endpoint domain: Mortality/survival
Primary endpoint: Change in STAI-assessed anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: noncardiovascular deaths
Endpoint domain: Mortality/survival
Primary endpoint: Blood neutrophil numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum SP-D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean improvement in ZAP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IRI levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in target behaviour for Intervention A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median attack rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Component Summary score change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: incremental QALY gain/child
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incremental cost/child
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Treatment response frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to treatment response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined endpoint of Aortic valve replacement, development of heart failure or cardiac death
Endpoint domain: Mortality/survival
Primary endpoint: Concentration of propofol required for adequate anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: successful termination of persistent AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cancer nursing knowledge test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive load score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Learning satisfaction and self-confidence score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: clinical gains in dyssynergic defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decline in blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Episodes of hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Cost per subject
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in missed days of work
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: center of pressure velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: isometric force during ankle dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of TWD episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of surgical treatment decision-making
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Agreement on the number of anastomoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DLQI impairment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle Mg(2+) content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Mg(2+) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mg(2+) loss in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average volume of skin bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Malaria infection reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of rape perpetration
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in collagen I C-terminal telopeptide (CrossLaps)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in total cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in LDL-cholesterol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: degree of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal serum aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: percentage of TIMI-3 flow in the IRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: blood flow in the IRA calculated with TIMI frame count method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of MACE
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of problem drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in percentage of body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in apo B levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in apo A-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: non-fatal haemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in clinical parameters (SCORAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in DLQ index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in immune activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TBIL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cephalic vein diameter change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: increases in moderate and vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increases in total physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak insulin concentrations (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the insulin concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Positive HCV RNA test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fasting dilute clot lysis time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting PAI‐1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean weight and length gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean length for age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAG AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TAG iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 3-week best spectacle-corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: appliance odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting triglyceride (TG) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pad weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes